CITA Biomedical, Inc. (DTOX)

[RowingDude]

Good morning DTOX - CITA Biomedical, Inc

[jmhollen]

Leading Chemical Dependency Recovery Center Successfully Begins Treating Patients With CITA Biomedical's Innovative Treatments for Alcohol, Cocaine, And Crack Dependence LCM Chemical Dependency Recovery Center Treats First DNA for Addictions Patient for Alcoholism

BEVERLY HILLS, Calif., Dec. 16 /PRNewswire-FirstCall/ -- CITA Biomedical, Inc. (OTC Bulletin Board: DTOX) a growing leader in the treatment of addiction dependency, today announced that Little Company of Mary (LCM) Chemical Dependency Recovery Center in San Pedro, California successfully began treating patients using CITA's Detoxification and NeuroAdaptation (DNA) for Addictions family of treatments. The first patient was treated for alcoholism with CITA's DNA for Alcohol. The DNA for Addictions treatment family includes DNA for Alcohol, DNA for Alcohol and Cocaine, DNA for Cocaine, and DNA for Crack Cocaine. CITA has patents pending for the family of DNA treatments.

The patient, a 55-year-old male who had been dependant on alcohol for 43 years was treated with DNA for Alcohol. The patient was consuming an average of one quart of alcohol daily. "I've tried several programs including Betty Ford, St. Joseph's, and I've been in and out of AA," said the patient. "The DNA for Alcohol treatment is miraculous! I continue to have no desire to drink and can't even remember what alcohol tastes like." The treatment was administered to the patient for less than an hour daily over two consecutive days and he experienced no withdrawal symptoms.

DNA for Addictions establishes a new treatment regimen in the fight against drug addiction, a disorder that impedes normal neural functioning of the brain and body systems as a whole. Addiction causes cravings, possible brain damage, and can lead to potentially life-threatening withdrawal symptoms. Historically, the disorder of addiction has been treated only through behavioral intervention, but the CITA DNA treatment provides a solution for treating both the physiological and psychological components of this devastating disease.

DNA for Addictions patients experience a less than 25 percent relapse rate, compared to a more than 75 percent relapse rate generally associated other accepted means of treating addiction. The new treatment was also shown to reduce the time, pain, and costs associated with withdrawal, and allowed the patients to return to a productive level of functioning within hours of the treatment's completion.

"Now that we have multiple centers serving California we're ready to open centers across the United States," said Joseph Dunn, president and CEO of CITA Biomedical. "The patient testimonial from LCM Chemical Dependency Recovery Center is similar to comments from all our patients treated so far. Treating both the physical and psychological components of addiction are key to DNA for Addictions' success and what sets DNA apart from any other treatments."

About CITA Biomedical, Inc.

CITA Biomedical, Inc., headquartered in Beverly Hills, Calif., focuses on the innovative treatment of addiction. The company holds the U.S. patent for its successful UROD (Ultra Rapid Opiate Detoxification) treatment method. UROD is the only clinically tested and effective treatment method to rapidly detoxify individuals addicted to opiate-based drugs, including heroin within four to six hours with few, if any, withdrawal symptoms. The company has a new family of revolutionary treatments, Detoxification and NeuroAdaptation (DNA) for Addictions. The first treatments from this family treat alcohol, cocaine, crack, and poly-drug addictions. To date, CITA has grown its business through internal expansion and now seeks compatible, leading, and complementing technologies and acquisitions to enhance its corporate portfolio. CITA Biomedical, Inc. has two operating divisions CITA Americas, Inc., and AltTPro, Inc. For more information, please visit www.citabio.com

About Little Company of Mary Chemical Dependency Recovery Center

Little Company of Mary Chemical Dependency Recovery Center in San Pedro is a non-profit alcohol and drug rehabilitation center affiliated with Little Company of Mary -- an integrated regional health care system serving the South Bay and Harbor communities of Los Angeles. For more than 25 years, the center has provided a full range of rehabilitative services at our facility, located adjacent to San Pedro Peninsula Hospital.

UROD is a registered trademark of CITA Biomedical, Inc.

Contacts:
Investor Relations Treatment Information
CITA Biomedical, Inc. Call: 1-888-400-2482
Judy Ryon, 310-550-4971 or
[e-mail] Visit: www.cita1.com
SOURCE CITA Biomedical, Inc.

CONTACT: Judy Ryon, Investor Relations of CITA Biomedical, Inc.,
[phone], [e-mail] ; or Treatment Information,
[phone]

Web site: http://www.citabio.com

http://www.cita1.com

.

Park your Sub at the iHub - Bub; .....the experience might just "...float your boat..." !!!

[jmhollen]

CITA Biomedical Begins Executive Search

BEVERLY HILLS, Calif., Dec. 13 /PRNewswire-FirstCall/ -- CITA Biomedical, Inc. (CITA) (OTC Bulletin Board: DTOX) a growing leader in the treatment of substance dependency, today announced that the search has begun for a new president and chief financial officer (CFO) to replace the departing president, Steven J. Rutlen and CFO, John Peters.

Both Mr. Rutlen and Mr. Peters are leaving CITA to pursue opportunities that are more inline with their interests and goals. CITA is aggressively working on recruiting top executives with experience in building companies and managing them through rapid growth. In the interim Joseph Dunn, chairman and CEO of CITA Biomedical will serve as president and CFO.

About CITA Biomedical, Inc.

CITA Biomedical, Inc., headquartered in Beverly Hills, Calif., focuses on the innovative treatment of addiction. The company holds the U.S. patent for its successful UROD (Ultra Rapid Opiate Detoxification) treatment method. UROD is the only clinically tested and effective treatment method to rapidly detoxify individuals addicted to opiate-based drugs, including heroin within four to six hours with few, if any, withdrawal symptoms. The company has a new family of revolutionary treatments, Detoxification and NeuroAdaptation (DNA) for Addictions. The first treatments from this family treat alcohol, cocaine, crack, and poly-drug addictions. To date, CITA has grown its business through internal expansion and now seeks compatible, leading, and complementing technologies and acquisitions to enhance its corporate portfolio. CITA Biomedical, Inc. has two operating divisions CITA Americas, Inc., and AltTPro, Inc. For more information, please visit www.citabio.com

UROD is a registered trademark of CITA Biomedical, Inc.

The information contained in this press release includes forward-looking statements. Forward-looking statements include declarations concerning plans, objectives, goals, strategies, future events and/or performance, and underlying assumptions and other statements which are other than statements of historical facts. Forward-looking statements usually contain the words "estimate," "anticipate," "believe," "expect" and other similar expressions that involve risks and uncertainties. These risks and uncertainties include, but are not limited to, the Company's status as a start-up enterprise with uncertain profitability, its need for significant capital, limited facilities, competition, uncertainty as to market acceptance of its services, and the protection of its intellectual property. The Company's actual results could differ materially from those expressed or implied in any forward-looking statements.

Contacts:
Investor Relations Treatment Information
CITA Biomedical, Inc. Call: 1-888-400-2482
Judy Ryon, 310-550-4971 or
[e-mail] Visit: www.citatreatment.com

SOURCE CITA Biomedical, Inc.

CONTACT: Judy Ryon of CITA Biomedical, Inc., [phone],
[e-mail], or CITA Biomedical Treatment Information, [phone]

Web site: http://www.citabio.com

http://www.citatreatment.com

[jmhollen]

CITA Biomedical Names Chief Financial Officer
John Peters, 20-year Financial Veteran, Joins CITA Biomedical Management Team

BEVERLY HILLS, Calif., Oct. 22 /PRNewswire-FirstCall/ -- CITA Biomedical, Inc. (CITA) (OTC Bulletin Board: DTOX) a growing leader in the treatment of substance dependency, today named John Peters as the company's Chief Financial Officer (CFO).

Mr. Peters brings to CITA over 20 years experience in the financial community. Most recently, Mr. Peters was a co-founding partner and Chief Financial Officer of Trilennia Group LLC. Previously, he was the Vice President of Finance for AutoWeb, an online business-to-business trading exchange for the automotive industry. John also served as Chief Financial Officer for PNBC, a web based trade show registration services provider. Over a fifteen-year period with KPMG he provided strategic audit and consulting services to both publicly traded and privately held companies.

(Photo: http://www.newscom.com/cgi-bin/prnh/19990413/LAPHOTO )

"We are extremely pleased that someone of John's caliber will be joining CITA," said Steve Rutlen, president of CITA Biomedical. "His track record and experience in building companies and managing them through rapid growth are very appealing at this stage in our business plan. As we roll-out our new treatment family, DNA for Addictions and expand our delivery channels across the U.S. and Canada, John's experience will be invaluable."

"I'm pleased to be joining a company that is committed to delivering high quality, safe addiction treatments for its customers," said Mr. Peters. "I believe CITA is poised for significant growth, expansion, and believe they have the potential to become the addiction treatment market leader."

In his role as CFO, Mr. Peters will be responsible for all aspects of the financial organization for CITA Biomedical, Inc. and subsidiaries. His appointment is effective immediately.

About CITA Biomedical, Inc.

CITA Biomedical, Inc., headquartered in Beverly Hills, Calif., focuses on the innovative treatment of addiction. The company holds the U.S. patent for its successful UROD (Ultra Rapid Opiate Detoxification) treatment method. UROD is the only clinically tested and effective treatment method to rapidly detoxify individuals addicted to opiate-based drugs, including heroin within four to six hours with few, if any, withdrawal symptoms. The company has a new family of revolutionary treatments, Detoxification and NeuroAdaptation (DNA) for Addictions. The first treatments from this family treat alcohol, cocaine, crack, and poly-drug addictions. To date, CITA has grown its business through internal expansion and now seeks compatible, leading, and complementing technologies and acquisitions to enhance its corporate portfolio. CITA Biomedical, Inc. has two operating divisions CITA Americas, Inc., and AltTPro, Inc. For more information, please visit http://www.citabio.com

UROD is a registered trademark of CITA Biomedical, Inc.

SOURCE CITA Biomedical, Inc.

CONTACT: investors, Judy Ryon of CITA Biomedical, Inc., [phone],
[e-mail], or Treatment Information, [phone]

PRN Photo Desk, [phone] or [phone]/

Web site: http://www.citatreatment.com

Web site: http://www.citabio.com

.

[jmhollen]

CITA Biomedical Appoints Steven J. Rutlen President and Chief Operating Officer
Former KPMG Executive to Assume Wide Range of Management Responsibilities

BEVERLY HILLS, Calif., Oct. 18 /PRNewswire-FirstCall/ -- CITA Biomedical, Inc. (CITA) (OTC Bulletin Board: DTOX) a growing leader in the treatment of substance dependency, today named Steven J. Rutlen as the company's president and chief operating officer (COO).

Rutlen brings over twenty years of operational and strategic planning experience to CITA. He recently retired from KPMG LLP, where he was western area Partner-in-Charge of KPMG's $120 million International Executive Services (IES) practice.

Mr. Rutlen also served as senior member of the firm's Executive Committee for the IES practice which set the strategic objectives and developed the operations plan to grow market share. He has experience in the addiction and healthcare field. During his tenure with KPMG he served as a Healthcare Practice consultant to healthcare providers including hospital and physicians groups as well as medical insurance companies.

"I am delighted that Steve has chosen to join CITA to lead our operations. As we refine our strategy and organization to meet the demands of our major market expansion as well as put us in position for long term growth, his experience will be invaluable," Joseph Dunn, chairman and CEO of CITA Biomedical. "Steve's expertise will help accelerate CITA's DNA for Addictions roll-out and market expansion across the U.S. and Canada."

"I am very pleased to be joining the CITA management team at this time," said Mr. Rutlen. "With an exciting new treatment family, DNA for Addictions and the expanded market opportunity it provides, CITA has a unique opportunity to capture a leading share of the addiction treatment market."

In his role as president and chief operating officer at CITA Biomedical, Mr. Rutlen will be responsible for day-to-day management of the company's core operations. His appointment is effective immediately.

About CITA Biomedical, Inc.

CITA Biomedical, Inc., headquartered in Beverly Hills, Calif., focuses on the innovative treatment of addiction. The company holds the U.S. patent for its successful UROD (Ultra Rapid Opiate Detoxification) treatment method. UROD is the only clinically tested and effective treatment method to rapidly detoxify individuals addicted to opiate-based drugs, including heroin within four to six hours with few, if any, withdrawal symptoms. The company has a new family of revolutionary treatments, Detoxification and NeuroAdaptation (DNA) for Addictions. The first treatments from this family treat alcohol, cocaine, crack, and poly-drug addictions. To date, CITA has grown its business through internal expansion and now seeks compatible, leading, and complementing technologies and acquisitions to enhance its corporate portfolio. CITA Biomedical, Inc. has two operating divisions CITA Americas, Inc., and AltTPro, Inc. For more information, please visit www.citabio.com

UROD is a registered trademark of CITA Biomedical, Inc.

For further information, please contact investors, Judy Ryon of CITA Biomedical, Inc., [phone], [e-mail]; or Treatment Information, [phone], www.citatreatment.com

SOURCE CITA Biomedical, Inc.

CONTACT: Judy Ryon of CITA Biomedical, Inc., [phone],
[e-mail]; or Treatment Information, [phone]/

Photo: http://www.newscom.com/cgi-bin/prnh/19990413/LAPHOTO

PRN Photo Desk, 888-776-6555 or 212-782-2840/

Web site: http://www.citatreatment.com

Web site: http://www.citabio.com

.

[jmhollen]

Leading Chemical Dependency Recovery Center to Offer CITA Biomedical's Groundbreaking Treatments for Alcohol, Cocaine, and Crack Dependence

San Pedro Hospital's Peninsula Chemical Dependency Recovery Center to Begin Treating Patients in Early October 2002

BEVERLY HILLS, Calif., Oct. 4 /PRNewswire-FirstCall/ -- CITA Biomedical, Inc. (OTC Bulletin Board: DTOX) a growing leader in the treatment of addiction dependency, today announced that it has reached an agreement with Little Company of Mary-San Pedro Hospital (LCM-SPH) in Los Angeles County, California to provide CITA's Detoxification and NeuroAdaptation (DNA) for Addictions family of treatments.

(Photo: http://www.newscom.com/cgi-bin/prnh/19990413/LAPHOTO )

The San Pedro Hospital's Peninsula Recovery Center will start treating patients with DNA for Addictions in early October. The DNA for Addictions treatment family includes DNA for Alcohol, DNA for Alcohol and Cocaine, DNA for Cocaine, and DNA for Crack Cocaine. CITA has patents pending for the family of DNA treatments.

"We are pleased to add the DNA treatments as an option for our patients suffering from substance dependency," said Dr. Crescenzo Pisano, Medical Director of LCM-SPH Peninsula Recovery Center. "The DNA technology now allows us to treat addiction at the source, providing renewed hope for those who were previously unresponsive to former treatment attempts. The combination of CITA's treatments and our recovery services provides our community with the most advanced and effective treatment options available, safely administered by our specially-trained medical professionals."

Addiction is a brain disease/disorder and DNA for Addictions treats addiction at the source. Historically the disease of addiction has been treated through behavioral intervention, but DNA for Addictions treatments provide a solution for treating the physiological and psychological components of this devastating condition. Substance abuse impedes normal neural functioning of the brain and body systems as a whole; resulting in cravings, potentially serious or even life-threatening withdrawal symptoms, and damage to the brain. The CITA DNA treatment reduces or eliminates cravings while correcting and regulating the neural functioning.

By providing successful detoxification and neural adaptation solutions that reduce the time, severity, pain and cost associated with withdrawal, the DNA for Addictions process allows the patient to concentrate on returning to a productive level of functioning in a very short time. DNA for Addictions treatments occur over two to three days, depending on the addiction(s) being treated. The process is performed under medical supervision followed by a continuing care program.

Completion rates for the DNA treatment process far exceed standard detoxification solutions, approaching a 100% completion rate. DNA for Addictions treatments have a relapse rate of less than 25%, in contrast with a relapse rate exceeding 75% for those people treated by other methods.

"By working together, CITA, LCM-SPH, and its highly competent medical staff are able to offer high-quality, safe, and cost-effective substance dependence recovery services," said Joseph Dunn, president and CEO of CITA Biomedical. "CITA's mission is to make the transition from substance dependence to independence as quick, smooth and humane as possible. With DNA for Addictions we've done that. We plan to continue to partner with leading treatment centers in order to make the DNA for Addictions treatment family widely available across the U.S. and Canada."

About CITA Biomedical, Inc.

CITA Biomedical, Inc., headquartered in Beverly Hills, Calif., focuses on the innovative treatment of addiction. The company holds the U.S. patent for its successful UROD (Ultra Rapid Opiate Detoxification) treatment method. UROD is the only clinically tested and effective treatment method to rapidly detoxify individuals addicted to opiate-based drugs, including heroin, within four to six hours with few, if any, withdrawal symptoms. The company has a new family of revolutionary treatments, Detoxification and NeuroAdaptation (DNA) for Addictions. The first treatments from this family treat alcohol, cocaine, crack cocaine, and poly-drug addictions. To date, CITA has grown its business through internal expansion and now seeks compatible, leading, and complementing technologies and acquisitions to enhance its corporate portfolio. CITA Biomedical, Inc. has two operating divisions CITA Americas, Inc., and AltTPro, Inc. For more information, please visit www.citabio.com.

About Little Company of Mary San Pedro Hospital

Little Company of Mary San Pedro Hospital is affiliated with Little Company of Mary Health Services. Little Company of Mary is an integrated, regional health care system serving communities in the South Bay area of Southern California comprised of more than 30 different medical and health care facilities and services, including Little Company Of Mary Hospital-Torrance and Little Company of Mary-San Pedro Hospital.

Little Company of Mary is a member of the Providence Health System. Providence Health System operates 20 acute care hospitals, 9 freestanding long-term care facilities, and 15 low-income and assisted living facilities. Providence Health System extends its mission of caring and commitment across a four-state area -- Alaska, Washington, Oregon, and Southern California. A comprehensive array of services is available to meet the varied needs of communities. These include acute and primary care, outpatient services, transitional care, home and hospice care, substance abuse programs, mental health treatment, comprehensive outreach programs including prevention and wellness, long-term care, and housing.

NOTE: UROD is a registered trademark of CITA Biomedical, Inc.

Contacts: Investor Relations Treatment Information
CITA Biomedical, Inc. Call: 1-888-400-2482
Judy Ryon, 310-550-4971 or
[e-mail] Visit: www.cita1.com

SOURCE CITA Biomedical, Inc.

CONTACT: Judy Ryon of CITA Biomedical, Inc., [phone], or
[e-mail], or Treatment Information, 1-888-400-2482

Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/19990413/LAPHOTO

AP Archive: http://photoarchive.ap.org

PRN Photo Desk, [phone] or [phone]/

Web site: http://www.cita1.com/

Web site: http://www.citabio.com/

[jmhollen]

CITA Biomedical Licenses Innovative Treatments for Alcohol, Cocaine, and Crack Dependence to Major California Medical Center
Freedom Treatment Center Treating Patients Successfully Since Early July

BEVERLY HILLS, Calif., Sept. 17 /PRNewswire-FirstCall/ -- CITA Biomedical, Inc. (OTC Bulletin Board: DTOX) a growing leader in the treatment of addiction dependency, today announced that it has signed a license agreement with Freedom Treatment Center in Southern California. The agreement enables Freedom Treatment Center to provide CITA's Detoxification and NeuroAdaptation (DNA) for Addictions family of treatments. Freedom Treatment Center has been successfully treating patients with DNA for Addictions since early July. The DNA for Addictions treatment family includes DNA for Alcohol, DNA for Alcohol and Cocaine, DNA for Cocaine, and DNA for Crack Cocaine. CITA has patents pending for the family of DNA treatments.

"DNA for Addictions family of treatments is an important option for our patients and community," said Dr. Morris Loffman, neurosurgeon and managing partner of Freedom Treatment Center. "Because this is the only service of its kind in this area, our community now has the most advanced and effective treatment options available to them. More important, the service is provided in a medical center setting and safely administered by Freedom's staff of very experienced doctors."

DNA for Addictions establishes a new treatment regimen in the fight against drug addiction, a disorder that impedes normal neural functioning of the brain and body systems as a whole. Addiction causes cravings, possible brain damage, and can lead to potentially life-threatening withdrawal symptoms. Historically, the disorder of addiction has been treated only through behavioral intervention, but the CITA DNA treatment provides a solution for treating both the physiological and psychological components of this devastating disease.

DNA for Addictions patients experience a less than 25 percent relapse rate, compared to a more than 75 percent relapse rate generally associated other accepted means of treating addiction. The new treatment was also shown to reduce the time, pain, and costs associated with withdrawal, and allowed the patients to return to a productive level of functioning within hours of the treatment's completion.

"We are pleased to be working with Freedom Treatment Center and its highly competent medical staff, to provide the DNA for Addictions family of treatments to their community," said Joseph Dunn, president and CEO of CITA Biomedical. "Treating both the physical and psychological components of addiction are key to DNA for Addictions' success and what sets DNA apart from other treatments. By working together, CITA and Freedom Treatment Center are able to offer high quality, safe, and cost effective addiction treatment services."

About CITA Biomedical, Inc.

CITA Biomedical, Inc., headquartered in Beverly Hills, Calif., focuses on the innovative treatment of addiction. The company holds the U.S. patent for its successful UROD (Ultra Rapid Opiate Detoxification) treatment method. UROD is the only clinically tested and effective treatment method to rapidly detoxify individuals addicted to opiate-based drugs, including heroin within four to six hours with few, if any, withdrawal symptoms. The company recently announced a new family of revolutionary treatments, Detoxification and NeuroAdaptation (DNA) for Addictions. The first treatments from this family treat alcohol, cocaine, and poly-drug addictions. To date CITA has grown its business through internal expansion and now seeks compatible, leading, and complementing technologies and acquisitions to enhance its corporate portfolio. CITA Biomedical, Inc. has two operating divisions CITA Americas, Inc., and AltTPro, Inc. For more information, please visit www.citabio.com .

About Freedom Treatment Center

Freedom Treatment Center is a medical center serving the San Fernando Valley area. The medical center offers a continuum of medical, surgical, and addiction services. The center is located at 16255 Ventura Boulevard, Suite 100, Encino, CA 91436. For more information, call 1-888-400-2482.

UROD is a registered trademark of CITA Biomedical, Inc.

For further information, please contact Investor Relations, Judy Ryon of CITA Biomedical, Inc., [phone], [e-mail]; or Treatment Information, [phone], www.cita1.com

SOURCE CITA Biomedical, Inc.

CONTACT: investors, Judy Ryon of CITA Biomedical, Inc., [phone],
[e-mail]; or Treatment Information, [phone]

Web site: http://www.cita1.com

Web site: http://www.citabio.com

.

[jmhollen]

Patient Treated for Alcoholism With CITA Biomedical's Proprietary Treatment Program to End Alcohol Dependence Remains Craving Free, No Withdrawal Symptoms, No Cravings for Alcohol

BEVERLY HILLS, Calif., Aug 7, 2002 /PRNewswire-FirstCall via COMTEX/ -- CITA Biomedical, Inc. (OTC Bulletin Board: DTOX) a growing leader in the treatment of substance dependency, today announced that the first U.S. Detoxification and NeuroAdaptation (DNA) for Alcohol patient continues to be craving free one month after treatment. DNA for Alcohol is a part of a family of treatments called DNA for Addictions. The DNA for Addictions treatment family also includes DNA for Cocaine, DNA for Alcohol and Cocaine, and DNA for Crack Cocaine. CITA has patents pending for the family of DNA treatments.

The patient said he is the happiest he has been in his life. He has even been able to enter a bar and have no desire for an alcoholic drink. Treated with DNA for Alcohol at the beginning of July the patient, a 62-year-old male who had been dependant on alcohol for over 40 years was consuming an average of 1.5 liters of gin, brandy, and beer a day. He is now saving the money he once spent on alcohol. The treatment was administered to the patient over two consecutive days where the patient experienced no symptoms of withdrawal.

DNA for Alcohol establishes an accelerated alcohol treatment in the fight against alcoholism, a disorder that impedes normal neural functioning of the brain and body systems as a whole. Alcoholism causes cravings, possible brain damage, and can lead to potentially life-threatening withdrawal symptoms. The disorder of alcoholism has historically been treated only through behavioral intervention, this is in contrast to CITA's DNA for Alcohol treatment which provides a solution for treating both the physiological and psychological components of this devastating condition.

Patients treated in Europe last year experienced a less than 25 percent relapse rate, compared to a more than 75 percent relapse rate generally associated other accepted means of treating alcoholism. The new treatment was also shown to reduce the time, pain, and costs associated with withdrawal, and allowed the patients to return to a productive level of functioning within hours of the treatment's completion.

"Treating both the physical and psychological components of alcoholism are key to DNA for Alcohol's success and what sets DNA apart from other treatments," said Joseph Dunn, president and CEO of CITA Biomedical. "We anticipate that the benefits this patient is experiencing will also be realized by the thousands of patients we plan to treat for alcohol dependence in the coming year. CITA's mission is to make the transition from substance dependence to independence as quick, smooth and humane as possible, with DNA for Addictions we've done that."

About CITA Biomedical, Inc.

CITA Biomedical, Inc., headquartered in Beverly Hills, Calif., focuses on the innovative treatment of addiction. The company holds the U.S. patent for its successful UROD (Ultra Rapid Opiate Detoxification) treatment method. UROD is the only clinically tested and effective treatment method to rapidly detoxify individuals addicted to opiate-based drugs, including heroin within four to six hours with few, if any, withdrawal symptoms. The company recently began a new family of revolutionary treatments, Detoxification and NeuroAdaptation (DNA) for Addictions. The first treatments from this family treat alcohol, cocaine, crack, and poly-drug addictions. To date CITA has grown its business through internal expansion and now seeks compatible, leading, and complementing technologies and acquisitions to enhance its corporate portfolio. CITA Biomedical, Inc. has two operating divisions: CITA Americas, Inc., and AltTPro, Inc. For more information, please visit www.citabio.com or www.cita1.com .

UROD is a registered trademark of CITA Biomedical, Inc.

For further information, please contact Judy Ryon of CITA Biomedical, Inc., [phone], [e-mail].

SOURCE CITA Biomedical, Inc.

CONTACT: Judy Ryon of CITA Biomedical, Inc., [phone], [e-mail]

.

Park your Sub at the iHub - Bub; ....the experience might just "...float your boat..." !!

[jmhollen]

I contacted a responsible "..dependency treatment physician.." in Des Moines about this subject, here is his response:

sorry for the delay, but i needed to consult an expert in treatment methodology.

the expert said, "The consensus is that there is no such treatment for
cocaine. NIDA has been researching one for years without success."

however, it is possible that the subject treatment may someday be proven
effective. the key will be recognition by the professional treatment
community and appropriate government agencies.

### #####


So, they are skeptical, but willing to look at documented results.

I don't think I'd fill up the footlocker with this one quite yet.


John

Park your Sub at the iHub - Bub; ....the experience might just "...float your boat..." !!

[jmhollen]

Here are the PRs on DTOX to date:

http://www.citabio.com/news.html


John

Park your Sub at the iHub - Bub; ....the experience might just "...float your boat..." !!